Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd1077010.32607/20758251-2010-2-1-88-93ArticlesСтатьиResearch ArticleTumoricidal Activity of RNase A and DNase ITumoricidal Activity of RNase A and DNase IPatutinaO Amarzen@niboch.nsc.ruMironovaN Lmarzen@niboch.nsc.ruRyabchikovaE Imarzen@niboch.nsc.ruPopovaN Amarzen@niboch.nsc.ruNikolinV Pmarzen@niboch.nsc.ruKaledinV Imarzen@niboch.nsc.ruVlassovV Vmarzen@niboch.nsc.ruZenkovaM Amarzen@niboch.nsc.ruInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of SciencesInstitute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences1503201021VOL 2, NO1 (2010)ТОМ 2, №1 (2010)889317012020Copyright ©; 2010, Patutina O.A., Mironova N.L., Ryabchikova E.I., Popova N.A., Nikolin V.P., Kaledin V.I., Vlassov V.V., Zenkova M.A.Copyright ©; 2010, Patutina O.A., Mironova N.L., Ryabchikova E.I., Popova N.A., Nikolin V.P., Kaledin V.I., Vlassov V.V., Zenkova M.A.2010Patutina O.A., Mironova N.L., Ryabchikova E.I., Popova N.A., Nikolin V.P., Kaledin V.I., Vlassov V.V., Zenkova M.A.Patutina O.A., Mironova N.L., Ryabchikova E.I., Popova N.A., Nikolin V.P., Kaledin V.I., Vlassov V.V., Zenkova M.A.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/10770

In our work the antitumor and antimetastatic activities of RNase A and DNase I were studied using two murine models of pulmonary (Lewis lung carcinoma) and liver (hepatoma A-1) metastases. We found that intramuscular administration of RNase A at the dose range of 0.1-50 μg/kg retarded the primary tumor growth by 20-40%, and this effect disappeared with the increase in RNase A dose over 0.5 mg/kg. DNase I showed no effect on the primary tumor growth. The intramuscular administration of RNase A (0.35-7 μg/kg) or DNase I (0.02-2.3 mg/kg) resulted in a considerable decrease in the metastasis number into the lungs of animals with Lewis lung carcinoma and a decrease of the hepatic index of animals with hepatoma 1A. A histological analysis of the organs occupied by metastases revealed that the administration of RNase A and DNase I induced metastasis pathomorphism as manifested by the destruction of oncocytes, an increase in necrosis and apoptosis foci in metastases, and mononuclear infiltration. Our data indicated that RNase A and DNase I are highly promising as supplementary therapeutics for the treatment of metastasizing tumors.

antimetastatic activityDNase IRNase ALewis lung carcinomahepatoma 1ADalmay T., Edwards D.R. // Oncogene. 2006. V. 25. no. 46. P. 6170-6175.Ardelt B., Ardelt W., Darzynkiewicz Z. // Cell Cycle. 2003. V. 2. no. 1. P. 22-24.Iorio M.V., Ferracin M., Liu C.G. et al. // Cancer Res. 2005. V. 65. no. 16. P. 7065-7070.Garcia-Olmo D., Garcia-Olmo D.C., Ontanon J. et al. // Blood. 2000. V. 95. no. 2. P. 724-735.Kotchetkov R., Cinatl J., Krivtchik A.A. et al. // Anticancer Res. 2001. V. 21. P. 1035-1042.Soucek J., Pouckova P., Matousek J. et al. // Neoplasma. 1996. V.43. no. 5. P. 335-340.Cinatl J.Jr., Cinatl J., Kotchetkov R. et al. // Int. J. Oncol. 1999. V. 15. no. 5. P. 1001-1009.Pouckova P., Zadinova M., Hlouskova D. et al. // J. Control Release. 2004. V. 95. no. 1. P. 83-92.Rybak S.M., Pearson J.W., Fogler W.E. et al. // J. Natl. Cancer Inst. 1996. V. 88. no. 11. P. 747-753.Lee I., Lee Y.H., Mikulski S.M. // J. Surg. Oncol 2000. V. 73. no. 3. P. 164-171.Costanzi J., Sidranski D., Navon A. et al. // Cancer Invest. 2005. V. 23. no. 7. P. 643-650.Ledoux L. // Nature. 1955. V. 175. no. 4449. P. 258-259.Ledoux L. // Nature. 1955. V. 176. no. 4470. P. 36-37.De Lamirande G. // Nature. 1961. V. 192. P. 52-54.Roth J.S. // Cancer Res. 1963. V. 23. P. 657-666.Klink T.A., Raines R.T. // J. Biol. Chem. 2000. V. 275. P. 17463-17467.Leland P.A., Schultz L.W., Kim B.M., Raines R.T. // Pro. Natl. Acad. Sci. USA. 1998. V. P. 10407-10412.Rutkoski T.J., Raines R.T. // Curr. Pharm. Biotechnol. 2008. V. 9. no. 3. P. 185-189.Wu Y., Mikulski S.M., Ardelt W. et al. // J. Biol Chem. 1993. V. 268. no. 14. P. 10686-10693.Kim J.S., Soucek J., Matousek J., Raines R.T. // J. Biol. Chem. 1995. V. 270. no. 18. P. 10525-10530.Sugihara S., Yamamoto T., Tanaka H. et al. // Br. J. Cancer. 1993. V. 67. P. 66-70.Tokita K., Sugihara S., Hiraoka T. et al. // Invasion Metastasis. 1995. V. 15. P. 46-59.Silberklang M., Gillum A.M., RhajBhandary // Methods Enzymol. 1979. V. 59. P. 58-109.Tomayko M.M., Reynolds C.P. // Cancer Chemother. Pharmacol. 1989. V. 24. P. 148-154.Klink T.A., Raines R.T. // Biol. Chem. 2000. V. 275. P. 17463-17467.Kim J.S., Soucek J., Matousek J. et al. // J. Biol. Chem. 1995. V. 270. P. 31097-31102.Matousek J. // Comp. Biochem. Physiol. C. 2001. V. 129. P. 175-191.Haigis M.C., Raines R.T. // J. Cell Sci. 2003. V. 116. P. 313-324.Zhao H., Ardelt B., Ardelt W. et al. // Cell Cycle. 2008. V. 7. P. 3258-3261.Sorrentino S., Naddeo M., Russo A. et al. // Biochemistry. 2003. V. 42. P. 10182-10190.Blaszczyk J., Gan J., Tropea J.E. et al. // Structure. 2004. V. 12. P. 457-466.Kojima K. // Nagoya J. Med. Sci. 1993. V. 56. P. 1-18.Ran S., Downes A., Thorpe P.E. // Cancer Res. 2002. V. 62. P. 6132-6140.Ilinskaya O.N., Dreyer F., Mitkevich V.A. et al. // Protein Sci. 2002. V. 11. P. 2522-2525.Ilinskaya O.N., Koschinski A., Mitkevich V.A. et al. // Biochem. Biophys. Res. Commun. 2004. V. 314. P. 550-554.Zhang B., Pan X., Cobb G.P. et al. // Dev. Biol. 2007. V. 302. P. 1-12.Wong T.S., Liu X.B., Wong B.Y. et al. // Clin. Cancer Res. 2008. V. 14. P. 2588-2592.Garzon R., Fabbri M., Cimmino A. et al. // Trends Mol. Med. 2006. V. 12. no. 12. P. 580587.Zhang B., Pan X., Cobb G. P. et al. // Dev. Biol. 2007. V. 302. no. 1. P. 1-12.Iorio M.V., Ferracin M., Liu C.G. et al. // Cancer Res. 2005. V. 65. no. 16. P. 7065-7070.Wong T.S., Liu X.B., Wong B.Y. et al. // Clin. Cancer Res. 2008. V. 14. no. 9. P. 2588-2592.Fauve R.M. // In: Azuma I., JollÈs G. (ed) Immunostimulants: Now and Tomorrow. 1987. Springer-Verlag, Berlin, pp.225-234.Januaz M., Wieczorek Z., Spiegel K. et al. // Mol. Immunol. 1987. V. 249. no. 10. P. 1029-1031.Vanhoof G., Goosens F., De Meester I. et al. // The FASEB Journal. 1995. V. 9. P. 736-744.